FindTrial
Sign In

Effect of mirtazapine and sertraline on BDI score and their link with serotonin transporter gene polymorphism in patients of Major depressive disorders .

THE RESPONSE TO TREATMENT WITH ANTI-DEPRESSANT DRUGSSERTARALINE VERSUS MIRTAZAPINE AND THEIR LINK WITH SEROTONIN TRANSPORTER GENEPOLYMORPHISM IN PATIENTS OF MAJOR DEPRESSIVE DISORDERS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/08/015172
Enrollment
80
Registered
2018-08-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Major Depressive Disorder

Interventions

Intervention1: The intervening drug is Mirtazapine and the comparator agent is sertraline.: Comparison of efficacy and safety of antidepressants agents sertraline and mirtazapine in patients of major

Sponsors

University College of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Major Depressive Disorder Patients of both sexes aged between 18 to 45 Years will be included

Exclusion criteria

Exclusion criteria: Study Participants will be excluded if they have Acute suicidal risk,dementia,schizophrenia,schizoaffective or bipolar diseases,post traumatic disorder,obsessive compulsive disorder ,anxiety,eating disorder,patient on any antidepressant,substance dependency,organic brain disease,pregnant and lactating women and any significant medical illness

Design outcomes

Primary

MeasureTime frame
BDI scores,BDI scale,SERT gene polymorphismTimepoint: BDI scores,BDI scale,SERT gene polymorphism—

Secondary

MeasureTime frame
noneTimepoint: 6 weeks—

Countries

India

Contacts

Public Contactsyed gulfishan

university college of medical sciences

sumitahalder123@rediffmail.com9899089556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026